Skip to main content
. 2022 Jul 11;11(14):4003. doi: 10.3390/jcm11144003

Figure 3.

Figure 3

KaplanMeier estimates in the whole cohort (p < 0.05, statistical significance; p < 0.001, significant statistical significance, red indicates); (A) Progression-free survival (ICIs/CHE vs. CHE vs. CHE/BEV = 16.9 months vs. 4.6 months vs. 7.0 months, p < 0.0001); (B) Overall survival (ICIs/CHE vs. CHE vs. CHE/BEV = 37.1 months vs. 19.8 months vs. 20.7 months, p = 0.014); (C) Objective Response Rate (ICIs/CHE vs. CHE vs. CHE/BEV = 47.4% vs. 31.1% vs. 21.2%).